Trials / Completed
CompletedNCT06448247
A Study of SPY001-001 in Healthy Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY001-001 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Spyre Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPY001-001 | Experimental |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2024-06-06
- Primary completion
- 2026-03-10
- Completion
- 2026-03-10
- First posted
- 2024-06-07
- Last updated
- 2026-03-20
Locations
2 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06448247. Inclusion in this directory is not an endorsement.